COMP241220C1500
- 0.00
- 0.000.00%
Compass Newsroom
Compass Is Maintained at Equal-Weight by Barclays
Compass Analyst Ratings
Barclays Maintains Compass(COMP.US) With Hold Rating, Raises Target Price to $7
Compass Price Target Raised to $7 From $6 at Barclays
Compass Group Completes Second Phase of Share Buyback
Compass Therapeutics Names Barry Shin CFO
Cullen/Frost Bankers Price Target Raised to $145.00/Share From $122.00 by Compass Point
Cullen/Frost Bankers Is Maintained at Neutral by Compass Point
Compass Point Maintains Buy on BankUnited, Raises Price Target to $49
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Giving Compass Announces New Leadership Appointments: Milan Ball and Kavitha Thimmaiah Join to Drive Philanthropic Partnerships and Donor Education
Compass Point Adjusts Price Target on Citizens Financial Group to $57 From $45, Keeps Buy Rating
Press Release: Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Compass (COMP) Shows Fast-paced Momentum But Is Still a Bargain Stock
Compass Point Adjusts Price Target on American Express to $315 From $260, Maintains Neutral
Compass Minerals Announces Conference Call to Discuss Fourth-Quarter and Fiscal 2024 Results
Compass Diversified to Host Investor Day on January 16, 2025, in New York City
Galaxy Digital Management to Meet With Compass Point
Barclays Remains a Buy on Compass (CPG)
Pennantpark Investment (PNNT) Receives a Hold From Compass Point